Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic via @FierceBiotech

Late last month, Gossamer Bio filed to raise up to $230 million in a fixed-price IPO so it could go public despite the partial shutdown of the U.S. government. Now that the government has reopened, the San Diego biotech has returned to its original plan, pricing its traditional IPO at $276 million. 

Source: Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic | FierceBiotech